The VISTA Consortium is powered by a collaborative network of leading academic institutions and industry partners united around scalable therapeutic discovery for rare and genetically defined diseases:
Partners
Academic Partners
Broad Institute of MIT and Harvard
As the consortium lead, the Broad Institute provides scientific leadership, image-based profiling infrastructure, and large-scale variant phenotyping capabilities to generate and analyze data for the Consortium. Drs. Anne Carpenter and JT Neal co-lead the consortium.
University of Toronto
Contributes foundational expertise in human genetics and variant functional characterization, collaborating on the generation and interpretation of disease phenotypes. Dr. Mikko Taipale leads the University of Toronto's efforts on VISTA.
Industry Partners
VISTA Industry Partners fund the data generation and analysis and bring insights on therapeutic strategies, drug selection, and machine learning to accelerate identifying candidate treatments across multiple rare diseases.
Ono Pharmaceutical Co., Ltd.
Ono's Kazumasa Shimofuruta is contributing to the data analysis effort of VISTA.
GSK
